8-1-2017

Application of Open-Access Databases to Determine Functional Connectivity Between Resveratrol-Binding Protein QR2 and Colorectal Carcinoma

Barbara B. Doonan  
New York Medical College

Evelien Schaafsma  
New York Medical College

John T. Pinto  
New York Medical College

Joseph M. Wu  
New York Medical College

Tze-Chen Hsieh  
New York Medical College

Follow this and additional works at: https://touroscholar.touro.edu/nymc_fac_pubs  
🔗 Part of the Amino Acids, Peptides, and Proteins Commons, Biochemistry Commons, and the Bioinformatics Commons

Recommended Citation

This Article is brought to you for free and open access by the Faculty at Touro Scholar. It has been accepted for inclusion in NYMC Faculty Publications by an authorized administrator of Touro Scholar. For more information, please contact jogrady@nymc.edu.
Application of Open Access Databases to determine functional connectivity between resveratrol binding protein QR2 and colorectal carcinoma

Barbara B. Doonan¹*, Evelien Schaafsma¹², John T. Pinto¹, Joseph M. Wu¹, Tze-chen Hsieh¹

Running Head QR2 Function and Colorectal Cancer

*Corresponding Author
Barbara B. Doonan
New York Medical College
15 Dana Road
Valhalla NY 10595, USA
doonanbarbara@yahoo.com
914-699-4415

¹Department of Biochemistry and Molecular Biology and ²Department of Cell Biology and Anatomy, New York Medical College, Valhalla, NY 10595, USA
ABSTRACT

Colorectal cancer (CRC) is a major cause of cancer-associated deaths worldwide. Recently, oral administration of resveratrol (trans-3,5,4’-trihydroxystilbene), has been reported to significantly reduce tumor proliferation in colorectal cancer patients, however, with little specific information on functional connections. The pathogenesis and development of colorectal cancer is a multi-step process that can be categorized using three phenotypic pathways, respectively, chromosome instability (CIN), microsatellite instability (MSI) and CpG island methylator (CIMP). Targets of resveratrol, including a high affinity binding protein, quinone reductase 2 (QR2), have been identified with little information on disease association. We hypothesize that the relationship between resveratrol and different CRC etiologies might be gleaned using publicly available databases. A web-based microarray gene expression data-mining platform, Oncomine, was selected and used to determine whether QR2 may serve as a mechanistic and functional biotarget within the various CRC etiologies. We found that QR2 mRNA is overexpressed in CRC characterized by CIN, particularly in cells showing a positive KRAS (Kirsten rat sarcoma viral oncogene homolog) mutation, as well as by the MSI but not the CIMP phenotype. Mining of Oncomine revealed an excellent correlation between QR2 mRNA expression and certain CRC etiologies. Two resveratrol associated genes, adenomatous polyposis coli (APC) and TP53 found in CRC were further mined, using cBio portal and Colorectal Cancer Atlas which predicted a mechanistic link to exist between resveratrol→QR2/TP53→CIN.

Multiple web-based data mining can provide valuable insights which may lead to hypotheses serving to guide clinical trials and design of therapies for enhanced disease prognosis and patient survival. This approach resembles a BioGPS, a capability for mining Web-based databases that
can elucidate the potential links between compounds to provide correlations of these interactions with specific diseases.

**Key Words** Oncomine; Colorectal Cancer Atlas; cBio Portal; Resveratrol; Colorectal Carcinoma (CRC); Quinone reductase 2

Oncomine is a readily available web-based platform that gives insight into cancer genomics by providing microarray datasets for different cancers ([www.oncomine.org](http://www.oncomine.org)) (Rhodes et al., 2004; Rhodes et al., 2007). The expression level of the $QR2$ gene in CRC was analyzed by searching the Oncomine database. The mRNA expression of $QR2$ in clinical samples of normal versus CRC patients and $QR2$ mRNA expression among different types of CRC were also compared. The cBio Cancer Genomics Portal ([http://cbioportal.org](http://cbioportal.org)) is a resource for exploring, visualizing, and analyzing data from multidimensional cancer genomics by reducing molecular profiles from cancer tissues and cell lines into understandable genetic, epigenetic, gene expression, and proteomic events. The query interface thus enables researchers to interactively explore genetic alterations across samples, genes, and pathways. This database (Cerami et al., 2012; Gao et al., 2013) was used to explore the connectivity of resveratrol associated genes across all CRC studies available in the databases. The Colorectal Cancer Atlas database ([http://www.colonatlas.org](http://www.colonatlas.org)) is an additional open platform accessed by using categorized lists of genes, sequence variations, cell lines and techniques (Chisanga et al., 2016). The gene information page includes features such as gene details, domain details, post-translational modifications, protein identification, sequence variations, pathways and protein-protein interactions. We explored the Colorectal Cancer Atlas to interactively probe the protein-protein network of resveratrol target $QR2$. Combined with Oncomine and the cBio Cancer Genomics Portal, the Colorectal Cancer Atlas
provided the third source for a workflow platform in categorizing molecular mechanisms of resveratrol and its association with clinical outcomes found in CRC.

Resveratrol has been shown to have chemopreventive effects in CRC and its utility in adjunctive therapy has been supported by clinical studies (Nguyen et al., 2009; Patel et al., 2010). We evaluated whether the gene of its high affinity target protein, QR2, can be used to generate hypotheses regarding chemopreventive efficacies of resveratrol on CRC with varying etiologies. The Oncomine database revealed that QR2 is correlated with CIN harboring the KRAS mutation; with statistically significant overexpression of QR2 mRNA occurring in KRAS-mutated compared to wild type KRAS carcinomas. KRAS (12p12.1) encodes a GTP-binding protein that, when mutated, can cause a loss of intrinsic GTPase activity and, accordingly, elicits constitutive signaling through the RAS-RAF-MEK-ERK cascade. Elevated levels of QR2 could conceivably increase demand for its co-substrate, N-ribosyl nicotinamide (NRN), by enhancing hydrolysis of NAD\(^+\) or NADP\(^+\). Reduction in the levels of NAD\(^+\) or NADP\(^+\) can result in an enhanced oxidized cellular environment. High expression of QR2 could also result in increased cellular levels of oxidized NRN which can cause G1/S cell cycle arrest and inhibit inosine 5′ monophosphate dehydrogenase (Gharehbaghi et al., 1994), an enzyme involved in de novo GTP biosynthesis. It is however noteworthy that an increased production of guanine nucleotides occurs in rapidly proliferating cells ultimately affecting the functioning of mutated KRAS. In addition, since NAD\(^+\) functions as the substrate for poly(ADP-ribose) polymerase 1 (PARP-1), a decrease in its level would diminish formation of poly (ADP-ribosylated) proteins that play key roles in several nuclear events that include DNA repair, replication, and transcription (Nakamura et al., 2003; Sauve, 2008). In a broader context, however, most studies listed (Table 1) contain insufficient details on the CIN pathway to CRC. This limits definitive evaluation of QR2 gene
expression in the CIN pathway for conclusive statements or hypotheses to be reached. The most pronounced QR2 changes were found in studies by Notterman et al. (2001) which showed an almost 400% increase in colon adenocarcinoma compared to healthy tissue. The study included patients from a wide age range (ages 30 to 89), from different races, early to advanced CRCs, male and female, and TP53 mutations (Table S1). Utilizing Oncomine to distinguish QR2 expression for each of these subgroups, we did not find correlations among QR2 expression and any of these characteristics. By excluding CIMP-high patients in this study and observing that the CIN pathway is more commonly found in patients (Table 2), we hypothesize that these QR2 mRNA alterations are correlated with the CIN etiology. However, the putative molecular determinants that underlie or contribute to the significant increase in QR2 expression in adenocarcinoma remain to be determined. By contrast, as observed in the top 10% of altered genes, Skrzypczak et al. (2010) reported a decrease in QR2 expression in epithelial adenoma compared to that in normal tissue. However, the study included only females, sporadic CRC cases and used unpaired controls. Gender differences do not play a role in QR2 expression in CRC, since almost all of the studies identified in Oncomine distinguish between males and females, but none showed gender differences in QR2 expression. The significance of this study is limited, however, by small sample size (10 healthy vs. 5 adenoma) and that cancerous tissue was not paired with adjacent non-involved mucosa.

The Oncomine database is available both as a subscription database and as open access. Although the free Oncomine version is very useful for generating general hypotheses regarding specific genes of interest, our analysis was limited by the paucity of gene expression data on QR2 and the lack of classification in several studies. To further elucidate the molecular mechanisms of resveratrol and its association with clinical outcomes found in CRC, cBio portal
for Cancer Genomics (http://cbioportal.org) (Cerami et al., 2012; Gao et al., 2013) and Colorectal Cancer Atlas (Chisanga et al., 2016) were included with Oncomine, building on our recently introduced functional/activity network (FAN) analysis (Hsieh et al., 2016). Through systematic query of the publicly available databases, respectively, Oncomine, cBio portal and Colon Cancer Atlas, we propose that bioefficacy of resveratrol observed in CRC patients operates by the following pathway: resveratrol→QR2/TP53→CIN pathway (intersected either by APC↔KRAS or APC↔PIK3CA).

This combined Oncomine-cBio Portal-Colorectal Cancer Atlas workflow platform engenders three simple steps: (i) identify resveratrol binding target QR2 and its association with the etiology of CRC using Oncomine (Rhodes et al., 2004; Rhodes et al., 2007), (ii) explore and verify whether genetic alterations exist for the identified resveratrol-associated genes/proteins across CRC samples in cancer genomics projects using cBio portal (Cerami et al., 2012; Gao et al., 2013) and (iii) explore Colorectal Cancer Atlas to interactively probe the protein-protein network of resveratrol target QR2. To our knowledge, this is a hitherto unexplored strategy that provides rationale as well as foundation in seeking certainty of biological plausibility.
**Funding**

This research was made possible with personal contributions for research support to TCH. The authors declare that the funding source has no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

**Authors’ contributions**

ES researched and performed the Oncomine query under supervision of TCH and wrote the first draft of the manuscript. ES received a Master’s of Science in Cell Biology, New York Medical College, Valhalla, NY. TCH. ES and JMW designed the research, analyzed the data, and wrote the early drafts of manuscript. BD, JTP edited and corrected the manuscript. BBD drafted this manuscript and corresponded with Dr. John Harbell at IVA for consideration of publication of this manuscript. All authors approved the final version of the manuscript.

**CONFLICTS OF INTEREST**

The authors declare no conflicts of interest.
REFERENCES


